AU2017224232B2 - Whole-cell cancer vaccines and methods for selection thereof - Google Patents

Whole-cell cancer vaccines and methods for selection thereof Download PDF

Info

Publication number
AU2017224232B2
AU2017224232B2 AU2017224232A AU2017224232A AU2017224232B2 AU 2017224232 B2 AU2017224232 B2 AU 2017224232B2 AU 2017224232 A AU2017224232 A AU 2017224232A AU 2017224232 A AU2017224232 A AU 2017224232A AU 2017224232 B2 AU2017224232 B2 AU 2017224232B2
Authority
AU
Australia
Prior art keywords
hla
gene
allele
cancer
drb3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017224232A
Other languages
English (en)
Other versions
AU2017224232A1 (en
Inventor
Markus Daniel Lacher
Joseph Paul WAGNER
William Valentine WILLIAMS
Charles Louis WISEMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Briacell Therapeutics Corp USA
Original Assignee
Briacell Therapeutics Corp USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Briacell Therapeutics Corp USA filed Critical Briacell Therapeutics Corp USA
Publication of AU2017224232A1 publication Critical patent/AU2017224232A1/en
Application granted granted Critical
Publication of AU2017224232B2 publication Critical patent/AU2017224232B2/en
Priority to AU2022259857A priority Critical patent/AU2022259857B2/en
Priority to AU2025205094A priority patent/AU2025205094A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/00112—Receptors for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017224232A 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof Active AU2017224232B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022259857A AU2022259857B2 (en) 2016-02-25 2022-10-28 Whole-cell cancer vaccines and methods for selection thereof
AU2025205094A AU2025205094A1 (en) 2016-02-25 2025-07-03 Whole-cell cancer vaccines and methods for selection thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662299674P 2016-02-25 2016-02-25
US62/299,674 2016-02-25
US201662425027P 2016-11-21 2016-11-21
US62/425,027 2016-11-21
PCT/US2017/019757 WO2017147600A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022259857A Division AU2022259857B2 (en) 2016-02-25 2022-10-28 Whole-cell cancer vaccines and methods for selection thereof

Publications (2)

Publication Number Publication Date
AU2017224232A1 AU2017224232A1 (en) 2018-09-06
AU2017224232B2 true AU2017224232B2 (en) 2022-07-28

Family

ID=59685619

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017224232A Active AU2017224232B2 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof
AU2022259857A Active AU2022259857B2 (en) 2016-02-25 2022-10-28 Whole-cell cancer vaccines and methods for selection thereof
AU2025205094A Pending AU2025205094A1 (en) 2016-02-25 2025-07-03 Whole-cell cancer vaccines and methods for selection thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022259857A Active AU2022259857B2 (en) 2016-02-25 2022-10-28 Whole-cell cancer vaccines and methods for selection thereof
AU2025205094A Pending AU2025205094A1 (en) 2016-02-25 2025-07-03 Whole-cell cancer vaccines and methods for selection thereof

Country Status (9)

Country Link
US (2) US11559574B2 (https=)
EP (1) EP3419657A4 (https=)
JP (1) JP6901505B2 (https=)
CN (1) CN109069603A (https=)
AU (3) AU2017224232B2 (https=)
CA (2) CA3015080A1 (https=)
IL (1) IL261354A (https=)
NZ (1) NZ745327A (https=)
WO (1) WO2017147600A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419657A4 (en) 2016-02-25 2019-11-06 Briacell Therapeutics Corp. CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF
AU2018378201A1 (en) * 2017-12-04 2020-05-21 Heat Biologics, Inc. Production of cell-based vaccines
EP3727467A4 (en) * 2017-12-22 2021-12-01 Centivax, Inc. MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE
CN108175853A (zh) * 2018-01-24 2018-06-19 上海赛群生物科技有限公司 一种肿瘤细胞疫苗及其制备方法
CN108486038B (zh) * 2018-03-21 2021-08-27 中国人民解放军第四军医大学 一种构建脂肪干细胞膜片的方法及应用
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
CN110938630B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人b3gnt5基因的用途及相关产品
US20250020652A1 (en) * 2021-11-18 2025-01-16 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based cancer treatments
IL315361A (en) 2022-03-03 2024-11-01 Briacell Therapeutics Corp Cancer vaccines and methods of use thereof
CN115433734B (zh) * 2022-06-01 2025-03-04 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用
CN117990593A (zh) * 2024-01-31 2024-05-07 南昌铭硕生科生物工程有限公司 一种流式多因子分析系统及其分析方法
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof
CN118207320A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-c*04:01基因的新用途及检测试剂盒
CN118207319A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-a*03:04基因的新用途及检测试剂盒
WO2026068517A1 (en) * 2024-09-24 2026-04-02 Universiteit Gent Cancer immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750102A (en) * 1992-03-13 1998-05-12 Yeda Research And Development Co., Ltd. Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
US20050276822A1 (en) * 2004-06-14 2005-12-15 Charles Wiseman Novel breast cancer cell lines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
JP2002536996A (ja) * 1999-02-22 2002-11-05 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ チロシンキナーゼ受容体ＥｐｈＡ３抗原ペプチド
WO2006081629A1 (en) 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy.
WO2006135454A1 (en) * 2005-06-08 2006-12-21 Saint Vincent Medical Center, A California Corporation Novel cancer cell lines and uses thereof
US20080020386A1 (en) 2006-03-29 2008-01-24 Medigen Biotechnology Corporation Methods and apparatus for genotyping
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2010045573A2 (en) 2008-10-17 2010-04-22 University Of Miami Tumor vaccine
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
EP3419657A4 (en) 2016-02-25 2019-11-06 Briacell Therapeutics Corp. CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750102A (en) * 1992-03-13 1998-05-12 Yeda Research And Development Co., Ltd. Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
US20050276822A1 (en) * 2004-06-14 2005-12-15 Charles Wiseman Novel breast cancer cell lines and uses thereof

Also Published As

Publication number Publication date
US20230277640A1 (en) 2023-09-07
NZ785587A (en) 2025-02-28
IL261354A (en) 2018-10-31
AU2017224232A1 (en) 2018-09-06
EP3419657A4 (en) 2019-11-06
JP6901505B2 (ja) 2021-07-14
CA3015080A1 (en) 2017-08-31
US20190046624A1 (en) 2019-02-14
NZ745327A (en) 2023-06-30
WO2017147600A1 (en) 2017-08-31
CA3300406A1 (en) 2026-03-02
AU2025205094A1 (en) 2025-07-24
US11559574B2 (en) 2023-01-24
EP3419657A1 (en) 2019-01-02
CN109069603A (zh) 2018-12-21
AU2022259857B2 (en) 2025-05-29
JP2019507608A (ja) 2019-03-22
AU2022259857A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
US20230277640A1 (en) Whole-cell cancer vaccines and methods for selection thereof
ES3042082T3 (en) Methods of making chimeric antigen receptor-expressing cells
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US20220152176A1 (en) Cancer biomarkers for durable clinical benefit
WO2019070755A1 (en) METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US20200352999A1 (en) Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US20230258635A1 (en) T cell phenotypes associated with response to adoptive cell therapy
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
US20210254097A1 (en) Engineering of immune cells for ex vivo cell therapy applications
WO2021035194A1 (en) Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
Lacher et al. SV-BR-1-gm, a clinically effective GM-CSF-Secreting breast cancer cell line, expresses an immune signature and directly activates CD4+ T lymphocytes
US20240398831A1 (en) Compositions comprising small molecule regulators of tumor immunity and methods of using same
US20240067970A1 (en) Methods to Quantify Rate of Clonal Expansion and Methods for Treating Clonal Hematopoiesis and Hematologic Malignancies
JP2025003730A (ja) 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法
Wu et al. Membrane palmitoylated protein MPP1 inhibits immune escape by regulating the USP12/CCL5 axis in urothelial carcinoma
JP2023515190A (ja) Ａｐｃ欠損がんの治療のための方法および組成物
CN118401562A (zh) 抗tnmuc1 gold car t细胞的组合物和方法
US20240156901A1 (en) Gal3bp polypeptide compositions and methods for treatment of cancer and determining treatment responsiveness
KR102872228B1 (ko) 폐암 치료 예후 예측용 신규 바이오마커 및 이의 용도
Davis Strategies to overcome Immunomodulatory drug resistance in multiple myeloma
US20240327520A1 (en) Methods and compositions for pkc-delta inhibition and cancer immunotherapy
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy
WO2025122856A1 (en) Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO BRIACELL THERAPEUTICS CORP.